OQROStart free trial
Politician trade (House)

Johnson & Johnson (JNJ): Rep. Josh Gottheimer (NJ05) disclosed a partial sale $1K–$15K

Rep. Josh Gottheimer (NJ05) disclosed a partial sale of Johnson & Johnson in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
35 days
Disclosure lag
Traded
Apr 9, 2025
Disclosed
May 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 7, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Jan 16, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Jan 21, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Jan 24, 2025Congress · 2 peopleMembers of Congress: 1 purchase, 1 sale
  5. Feb 7, 2025InsiderCFO sold ~$2M of JNJ shares in the open market
  6. Feb 18, 2025InsiderChair sold ~$63K of JNJ shares in the open market
  7. Feb 24, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  8. Feb 25, 2025InsiderOfficer sold ~$1.16M of JNJ shares in the open market
  9. Mar 3, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  10. Mar 4, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  11. Mar 5, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  12. Mar 7, 2025FDARecall: PDS¿PLUS¿VIO¿30IN(75CM)¿USP6-0(M0.7)¿D/A¿C-1¿MP
  13. Mar 7, 2025FDARecall: PROLENE BLU 18IN(45CM) USP6-0(M0.7) S/A P-1 PRM
  14. Mar 7, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  15. Mar 20, 2025FDAFDA drug approval: Tremfya
  16. Mar 21, 2025FDAFDA drug approval: Prezcobix
  17. Mar 24, 2025CongressDisclosed sale of JNJ — reported range $100,001 - $250,000
  18. Mar 28, 2025FDAFDA device clearance: Synthes Graphic Case & Tray System
  19. Mar 31, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  20. Apr 1, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  21. Apr 8, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  22. Apr 9, 2025 · this disclosureCongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000

What came next

  1. Apr 10, 2025FDAFDA drug approval: Darzalex
  2. Apr 21, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  3. Apr 22, 2025FDARecall: Endopath Echelon Vascular White Reload for Advanced Placement Tip (35mm, 4 row); Product code VASECR35
  4. Apr 24, 2025FDAFDA device clearance: MENTOR™ PliaForm™ Breast Tissue Expander w/ Suture Tabs
  5. Apr 29, 2025FDAFDA drug approval: Imaavy
  6. Apr 29, 2025Congress · 1 personMembers of Congress: 2 sales
  7. May 2, 2025FDAFDA device clearance: Shockwave CS Guide Catheter
  8. May 5, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  9. May 12, 2025CongressDisclosed sale of JNJ — reported range $50,001 - $100,000
  10. May 14, 2025FDAFDA device clearance: ETHICON 4000 60mm Compact Stapler (EC3D60C); ETHICON 4000 60mm Standard Stapler (EC3D60S); ETHICON 4000 60mm Long Stapler (EC3D60L); ETHICON 3D 60mm White Relo…
  11. May 23, 2025FDAFDA device clearance: RECLAIM Monobloc Revision Femoral Stem
  12. May 30, 2025CongressDisclosed purchase of JNJ — reported range $15,001 - $50,000
  13. Jun 10, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  14. Jun 12, 2025FDARecall: ACUVUE¿ OASYS MAX 1-Day MULTIFOCAL
  15. Jun 12, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  16. Jun 16, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  17. Jun 23, 2025FDARecall: Automated Impella Controller (AIC), used in left heart support blood pump, including the following: 1. Impella Controller, Packaged, AU; Product Code: 0042-000…
  18. Jul 17, 2025InsiderOfficer sold ~$3.13M of JNJ shares in the open market
  19. Jul 28, 2025FDAFDA drug approval: Sirturo
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 14 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 119 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

Other recent filings by Rep. Josh Gottheimer (NJ05)

The full history of Rep. Josh Gottheimer (NJ05) is on the profile page.

How this filing works

Explore the data

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Start free trialAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data